Imago

Merck Announces Third-Quarter 2023 Financial Results

Retrieved on: 
Thursday, October 26, 2023
Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, Diabetes, Infectious Diseases, Clinical Trials, Ezetimibe, Vaccine, Prometheus, News, Merck, GAAP, ADC, Daiichi Sankyo, EPS, Webcast, Investment, Pharmaceutical industry, Fine chemical, Bank, Rare-earth element, Imago

These items are inherently difficult to forecast and could have a significant impact on the company’s future GAAP results.

Key Points: 
  • These items are inherently difficult to forecast and could have a significant impact on the company’s future GAAP results.
  • Merck now expects full-year sales to be between $59.7 billion and $60.2 billion, including a negative impact of foreign exchange of approximately 2 percentage points, at mid-October 2023 exchange rates.
  • Merck now expects its full-year non-GAAP EPS to be between $1.33 and $1.38, including a negative impact of foreign exchange of approximately 6 percentage points, at mid-October 2023 exchange rates.
  • A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, prepared remarks and slides highlighting the results, will be available at www.merck.com .

Global Myeloproliferative Disorders Drugs Research Report 2023: Market is Expected to Surpass $10.5 Bn in 2027 - Focus on JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Pharmaceutical, Health, Incidence, Imago, Bristol Myers Squibb, Nilotinib, Pancreatic serous cystadenoma, Primary myelofibrosis, FDA, Ageing, Radiation exposure, Merk, Growth, Bone marrow, Polycythemia, DSM-IV codes, Chronic myelogenous leukemia, Foundation for the National Institutes of Health, Pharmaceutical industry

The "Myeloproliferative Disorders Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myeloproliferative Disorders Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • In the rapidly advancing pharmaceutical landscape, the significance of myeloproliferative disorder drugs is more pronounced than ever.
  • Driving the surge in the market for these drugs is the escalating incidence of myeloproliferative disorders.
  • The countries covered in the myeloproliferative disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

Retrieved on: 
Wednesday, January 11, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, MSD, Eastern Time Zone, Acquisition, MRK, NYSE, Security (finance), Holding company, Imago, Merck

As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago’s outstanding shares on a fully diluted basis.

Key Points: 
  • As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago’s outstanding shares on a fully diluted basis.
  • All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.
  • Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago, with Imago being the surviving corporation, in which all shares not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $36.00 offer price per share, without interest and subject to deduction for any required tax withholding.
  • After the completion of the merger, Imago will become a wholly owned subsidiary of Merck and the common stock of Imago will no longer be listed or traded on the Nasdaq Global Market.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, AJRD, QUMU, MPB

Retrieved on: 
Thursday, December 22, 2022
Qumu Corporation, Fraud, Aerojet Rocketdyne Holdings, Aerojet, NYSE, Advertising, L3Harris Technologies, Sale, Security (finance), Imago, Merck

If you are an Imago shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Imago shareholder, click here to learn more about your rights and options .
  • If you are an Aerojet shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

Retrieved on: 
Tuesday, December 20, 2022
Imago, MF, Ruxolitinib, Food, Pancreatic serous cystadenoma, Hong Kong residents, Regulation of tobacco by the U.S. Food and Drug Administration, Department of Medicine – University of Pamplona, LSD1, Patient, Safety, University, FDA, Megakaryocyte, Bone marrow, Pharmaceutical industry

Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF.

Key Points: 
  • Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF.
  • The Phase 2 open-label study is being conducted at the Department of Medicine, Queen Mary Hospital and the University of Hong Kong and led by Harinder Gill, M.D.
  • Treatment cycles will last for 28 days, consisting of an oral administration of both bomedemstat and ruxolitinib once daily.
  • “We are excited that the University of Hong Kong has interest in exploring the potential use of bomedemstat in combination with ruxolitinib for the treatment of myelofibrosis,” said Hugh Y. Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, IMGO, FORG, USER

Retrieved on: 
Wednesday, December 14, 2022
Advertising, Sale, Fraud, NYSE, Thoma Bravo, Security (finance), Indivior, Imago, Merck

If you are an Opiant shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Opiant shareholder, click here to learn more about your rights and options .
  • If you are an Imago shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022

Retrieved on: 
Monday, December 12, 2022
ASXL1, Dysgeusia, Pancreatic serous cystadenoma, European Medicines Agency, EMA, Intellectual property, Sumathi Best Television Current Reporting Award, Annual report, MF, Week, TSS, Congress, Sale, AE, EHA, Safety, Bone marrow, Hematology, Cancer, JAK2, ET, Priority, Trial of the century, Good manufacturing practice, ASH, HMR, MAF, Blood, AML, Acute myeloid leukemia, Șaeș, Fibrosis, Society, Ruxolitinib, LSD1, Fast track (FDA), Patient, Anemia, Pharmaceutical industry, Imago

REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).

Key Points: 
  • (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
  • The data were presented in a poster presentation session during the 64th American Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022.
  • A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30th European Hematology Association Annual Meeting and congress (EHA) in June 2022.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185).

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022

Retrieved on: 
Monday, December 12, 2022
MPL, European Medicines Agency, Annual report, Diarrhea, Fatigue, Sale, EHA, ET, Priority, ASH, Thrombocytopenia, HIV disease progression rates, Granulocyte, Observation, Dysgeusia, Pancreatic serous cystadenoma, EMA, Congress, FDA, Arthralgia, Safety, Cancer, Bruise, Bone marrow, Blood, Constipation, CALR, Șaeș, Society, LSD1, TSS, JAK2, Trial of the century, Good manufacturing practice, Mutation, Ruxolitinib, Fast track (FDA), Hematology, Patient, Intellectual property, Sumathi Best Television Current Reporting Award, MF, AES, Platelet, Death, Causality, Health insurance, Beef cattle, Pharmaceutical industry, Imago

The data were presented in an oral presentation session during the 64th American Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022.

Key Points: 
  • The data were presented in an oral presentation session during the 64th American Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022.
  • A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30th European Hematology Association Annual Meeting and congress (EHA) in June 2022.
  • Of the 62 Patients treated with bomedemstat for more than 24 weeks:
    100% (62/62) achieved platelet count reduction to ≤ 400 x 109/L.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185).

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, IMGO, SAL

Retrieved on: 
Thursday, December 8, 2022
Advertising, Sale, Fraud, NBT, Security (finance), Indivior, Imago, Merck

If you are an Opiant shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Opiant shareholder, click here to learn more about your rights and options .
  • If you are an Imago shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

EQUITY ALERT: Contact the M&A Class Action Firm to Inquire about its Investigation of the Merger – LBAI, SBCF, IMGO, SRYB

Retrieved on: 
Wednesday, December 7, 2022
Empire, Acquisition, Merck, Imago, Lawyer, Security (finance), SBCF, Provident Bank of New Jersey, United States Court of Appeals for the Ninth Circuit, OTC, Merck & Co., First Community Bancshares, Supreme court, Telephone, Monteverde, Martindale-Hubbell, Investment, Mergers and acquisitions, Provident, Greenhouse effect (United States Supreme Court), Rising Star

Under the terms of the merger, LBAI shareholders will receive 0.8319 shares of Provident per share they own.

Key Points: 
  • Under the terms of the merger, LBAI shareholders will receive 0.8319 shares of Provident per share they own.
  • Under the terms of the merger, Professional Holding Corp. shareholders are expected to receive 0.8909 shares of SBCF per share they own.
  • We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.
  • Also, we have recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.